SNT

2.27%

4.3¢ syntara limited

Ann: Investor presentation, page-14

First 14 Last

Share
Profile

Follow
ma420

7,168 Posts.

1834

03/07/24

15:03

Post #: 74589631
Share

Originally posted by Grainofsand: ↑

You've probably seen this video already, but if you haven't -

Apart from what you already mention, another key catalyst will be the interim trial results for the SNT-5505 Phase 2amyelofibrosiscombination study, which is almost fully recruited for (80% there), locked in to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Likely to be a significant inflection point and an opportunity to raise money at a premium, if required.

My primary reasons for investing:
- 1 year cash runway
- 3 or 4 different Phase 2 trial results all due by mid-2025
- Positive data from SNT 5505 monotherapy study! It's interim Ph2 data is due in Dec '24 as mentioned above
- SNT 5505 - demonstrated reduction in bone marrow fibrosis AND demonstrated improvement in scar appearance
- Company has worked with Fiona Wood for 5 years on scar treatment. There are no other pharma treatments in development and Fiona Wood saw the full inhibition of L enzymes, and the 30% reduction of collagen in scars, over only a 3-month period, as UNPRECEDENTED! Trial patients still continue to improve after the end of the trial.
- Management have taken serious steps to reduce costs and stretch funds
- $10m raised late last year from institutions at 2.2c. Platinum Investments increasing their holding from 8-20%. As a friend of mine said - these institutions employ people to do due diligence on their investments - if an investment is good enough for them, then it's good enough for me!
- I haven't checked but CEO advises of a super strong register of investors with 60% being instos
- Focus by company - cancer of the blood and skin scarring
- Huge potential market for just one of these products, let alone more than one. I think market exposure for all was something like $15b!
- Some people, who I value as knowing a lot more about bios than myself, think SNT is an exceptional buying opportunity! Works for me!

Expand

Many thanks for the great summary. Will watch the video later.

One fundie I met yesterday is personally invested here but what was interesting when discussing other biotechs was he has very biased view of certain executives or drugs or companies. Human minds, once you form an opinion hard to change it!

I had known this company by its old name. Now started watching this after this fundie put it to my radar.

Multiple irons in the fire is good but the company/ drugs need to deliver. A billion+ SOI isn’t the best IMO. Will keep learning.

AIMO.

SNT Price at posting: 2.4¢ Sentiment: None Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 30 more messages in this thread...

First 14 Last

Add SNT (ASX) to my watchlist

(20min delay)
Last 4.3¢		Change -0.001(2.27%)		Mkt cap ! $59.04M

Open	High	Low	Value	Volume
4.4¢	4.4¢	4.2¢	$39.11K	895.4K

Buyers (Bids)

No.	Vol.	Price($)
1	752779	4.3¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	752779	0.043
1	590	0.042
3	1060000	0.041
8	1482500	0.040
1	200000	0.039

Price($)	Vol.	No.
0.044	200000	1
0.045	591528	2
0.046	142712	2
0.049	68444	2
0.050	20000	1

Last trade - 15.58pm 04/10/2024 (20 minute delay)

SNT (ASX) Chart

Ann: Investor presentation, page-14

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor presentation, page-14

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News